Impact of topical testosterone on lipid profile in women with decreased sexual desire: A randomized controlled double-blind study.

Not Applicable

• Conditions: Absence or reduction of sexual desire; Hypoactive Sexual Desire Disorder; F03.835

• Registration Number: RBR-8kmydzj
• Lead Sponsor: universidade federal de sao paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-10-02
• Study Start: 2021-11-03
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Data analysis completed
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women over 18 years old; maximum age 45 years; Decreased sexual desire; Present sexual activity, with at least one sexual event per month, with current partner; Be in good general health; Women over 40 should have a clinically acceptable mammogram within the last 2 years; Be on contraceptive method.

Exclusion Criteria

Exclusion Criteria:Sexual dysfunction caused by another medical condition;Body mass index (BMI) below 18 kg / m2 or above 35 kg / m2; undiagnosed genital bleeding;Use of androgen therapy in the last 6 months (testosterone implant, testosterone transdermal cream, tibolone, oral testosterone or injectable testosterone); Antiandrogenic therapy for acne or hirsutism in the last 5 years; Hyperandrogenism Syndrome, such as Polycystic Ovary Syndrome; Moderate or severe acne, hirsutism, and androgenetic alopecia; Any serious clinical or psychiatric illness, active cancer, or treatment of malignancy within the last six months; Decompensated clinical disease; Any clinically significant skin abnormalities in the study medication application area; Consumption of more than three standard alcoholic drinks per day; pregnancy or lactation; Do not attend our center for follow-up study visits.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome:The primary outcome of the study will be the effect of testosterone at the treatment dose for Hypoactive sexual desire on lipid profile;

Secondary Outcome Measures

Name	Time	Method
Secondary Outcome: As secondary outcomes will be assessed the suffering associated with low desire, which will be measured using FSFI. The change in sexual function as measured by the FSFI, which should be assessed at baseline and week 12. Possible side effects will also be assessed. As well as other laboratory parameters previously mentioned.